Cancer Diagnostic Probe

The Cancer Diagnostic Probe (CDP) is a medical device used in Iran during breast cancer surgery.[1][2] First developed by Nano Hesgar Sazan Salamt Arya, an Iranian company,[1] CDP has received medical approval in Iran, where it is used in surgical centers.[2]

Development and application

The Cancer Diagnostic Probe was developed by a team led by Mohammad Abdolahad, a 2019 Mustafa Prize laureate and faculty member of the School of Electrical and Computer Engineering at the University of Tehran, to facilitate the determination of cancerous margins.[2] Abdolahad stated that the clinical trial for the device lasted 4 years and that up to 500 surgeries had been carried out using the CDP by 2020.[2] According to Sayyed Ruhollah Miri, the head of the Cancer Institute at the Tehran University of Medical Sciences, the CDP reduces the diagnosis time to 1–2 minutes.[3]

Mechanism

The CDP device is composed of three main parts: "a disposable sensor; a wireless electrical head probe used by the surgeon; [and] a main control computer system which receives the signals from the head probe".[2] It electrochemically measures the hypoxia glycolysis metabolism in real-time "in pre-cancerous and cancerous lesions in cavity side margins".[1] It measures the release of H2O2 from cancer or atypical cells by the reverse Warburg effect.[1][4]

Reception

The development of CDP was supported by the Iranian Nano Technology Development Headquarters.[3] After receiving medical approval, this system has been used in breast cancer surgeries in Iran.[2] As of 2022, four U.S. patents have been published related to CDP.[5]

References

  1. ^ a b c d "Real-time Cancer Diagnostic Probe – Iran Advanced Clinical Training Center". Tehran University of Medical Sciences. Archived from the original on 14 January 2023. Retrieved 10 January 2023.
  2. ^ a b c d e f "Mustafa (pbuh) Prize laureate presented his Cancer Diagnostic Probe". Mustafa Prize. Archived from the original on 14 January 2023. Retrieved 10 January 2023.
  3. ^ a b "The visit of a delegate of Indian businessmen and doctors to the achievement of Iranian researchers in the treatment of breast cancer". Iranian nanotechnology newsletter (in Persian). 9 January 2023. Archived from the original on 14 January 2023. Retrieved 12 January 2023.
  4. ^ Dabbagh, Najmeh; Abbasvandi, Fereshteh; Miripour, Zohreh Sadat; et al. (2022). "Accuracy of cancer diagnostic probe for intra-surgical checking of cavity side margins in neoadjuvant breast cancer cases: A human model study". The International Journal of Medical Robotics and Computer Assisted Surgery. 18 (1) e2335. doi:10.1002/rcs.2335. ISSN 1478-5951. PMID 34571582. S2CID 238204138. Archived from the original on 14 January 2023. Retrieved 14 January 2023.
  5. ^ Miripour, Zohreh Sadat; Abbasvandi, Fereshteh; Aghaee, Parisa; et al. (2022). "Human study on cancer diagnostic probe (CDP) for real-time excising of breast positive cavity side margins based on tracing hypoxia glycolysis; checking diagnostic accuracy in non-neoadjuvant cases". Cancer Medicine. 11 (7): 1630–1645. doi:10.1002/cam4.4503. ISSN 2045-7634. PMC 8986141. PMID 35224879.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.